Histone acetylation and histone deacetylase (HDAC) activity is one of the most extensively studied epigenetic marks [214], and HDAC inhibitors are considered potential therapeutic agents for neurodegeneration associated with ischemic stroke [215,216,217], renal, and cardiac IR injuries [218,219,220,221,222]. Here, HDAC9 is linked to ischemic stroke.